Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Metformin for Weight Loss in Schizophrenia

This study has been terminated.
(PI moved to differetnt institution. Decided to concentrate on different studies.)
Information provided by (Responsible Party):
Robert C. Smith MD PhD, Nathan Kline Institute for Psychiatric Research Identifier:
First received: April 23, 2010
Last updated: December 15, 2016
Last verified: December 2016
Study hypothesis is that patients on antipsychotics medication treated with metformin will show loss in weight and improved measures of glucose metabolism.

Condition Intervention
Drug: Metformin

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Evaluation of the Efficacy of Metformin for Weight Loss and Metabolic Effects In Overweight Psychiatric Patients Treated With Antipsychotic Medication

Resource links provided by NLM:

Further study details as provided by Nathan Kline Institute for Psychiatric Research:

Primary Outcome Measures:
  • Weight in Lbs. [ Time Frame: baseline, 4 wks, 8 wks, 12 weeks ]
    Patients weight in pounds

Secondary Outcome Measures:
  • Glucose Levels [ Time Frame: baseline, 4 weeks, 8 weeks, 12 weeks ]
    Fasting glucose

  • Insulin Level [ Time Frame: baseline, 4 weks, 8 weeks, 12 weeks ]
    fasting serum insulin

Enrollment: 12
Study Start Date: May 2008
Study Completion Date: April 2011
Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Metformin Drug: Metformin
metformin 500- 2500 mg/day.

Detailed Description:
Patients who had gained more than 10 lbs of weight in the last 3 months or had BMI of 35 or greater were treated with metformin up to 200 mg/day in an open label study of up to 3 months time. Changes in weight and glucose measures were recorded.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients will be 18-70 years of age;
  • Currently hospitalized or an outpatient at MPC;
  • BMI ≥ 35 or excessive recent weight gain ( > than 10 lb weight gain in the past 3 months);
  • Patients will have a diagnosis of schizophrenia or schizoaffective disorder or bipolar disorder.

Exclusion Criteria:

  • Age below 18 or over 70;
  • Patient is currently already treated with metformin.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01177709

United States, New York
Manhatan Psychiatric Center
New York, New York, United States, 10035
Sponsors and Collaborators
Nathan Kline Institute for Psychiatric Research
  More Information

Responsible Party: Robert C. Smith MD PhD, Research Psychiatrist-Principal investigator, Nathan Kline Institute for Psychiatric Research Identifier: NCT01177709     History of Changes
Other Study ID Numbers: 091/C22
Study First Received: April 23, 2010
Results First Received: December 15, 2016
Last Updated: December 15, 2016

Keywords provided by Nathan Kline Institute for Psychiatric Research:

Additional relevant MeSH terms:
Weight Loss
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Body Weight Changes
Body Weight
Signs and Symptoms
Antipsychotic Agents
Hypoglycemic Agents
Physiological Effects of Drugs
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs processed this record on May 22, 2017